Altis Biosystems

🌐 Why use in vitro models to study inflammatory bowel disease? IBD affects millions worldwide. Developing effective treatments requires models that accurately capture disease pathology. In vitro platforms are stepping up, especially with human stem-cell derived systems that mimic the intestinal environment. Here’s why in vitro models bring value to IBD research: 👩🔬 Human-Relevant Insights: Human-derived cell culture models closely mimic the human gut environment. This relevance is crucial for IBD research, as it offers insights more directly translatable to human biology and potential treatments. ⚡High-Throughput Screening: In vitro models are ideal for screening large libraries of compounds quickly and efficiently. This accelerates the identification of promising therapeutic candidates that could help modulate inflammation and restore barrier function in IBD. 🧪 Controlled Environment: In vitro models allow for precise control over experimental conditions, making it easier to study specific aspects of IBD pathology (e.g., barrier integrity, immune responses) without the variability of in vivo systems. 🐾 Reduction in Animal Use: In vitro models reduce the need for animal testing by providing an alternative platform for early-stage research, aligning with ethical standards and improving feasibility for large-scale studies. 💰 Cost-Effectiveness and Speed: In vitro studies are generally faster and more cost-effective than in vivo models, enabling quicker hypothesis testing and early-stage evaluation of treatment efficacy. 🔬 Mechanistic Insights: By using specific readouts like TEER, cytokine release, and cell viability, in vitro models allow researchers to pinpoint mechanisms of action, such as how a treatment affects barrier integrity or inflammatory signaling, which is valuable for drug development. Our RepliGut® platform is optimized for screening anti-inflammatory leads and advancing our understanding of IBD, bringing us closer to more effective treatments. We’re proud to support these critical efforts in the fight against IBD. Learn more: https://hubs.ly/Q02XghRy0

Heading to #ACT2024? Stop by our posters to meet Ben Scruggs and Colleen Pike who will be sharing our innovative approaches in toxicology and drug discovery. Visit us at booth 205 to connect and learn about our RepliGut® solutions. 📅 Date: November 18-19, 2024 📍 Location: JW Marriott, Austin, Texas

Rapidly screen for anti-inflammatory leads using Repligut® Planar. Using InflammaScreen™ Services, you can assess multiple endpoints of inflammation including cellular toxicity, barrier integrity, and IL-8 chemokine secretion. Learn more: https://hubs.ly/Q02WNrgg0

💡 Modeling Diarrhea In Vitro: Understanding Barrier Integrity with TEER Diarrhea is a common adverse event associated with many medications, including antibiotics and chemotherapy agents. In vitro models that are compatible with Trans-Epithelial Electrical Resistance (TEER) measurements have become essential tools for predicting diarrhea risk. 📖Here’s why: 1️⃣ What is TEER? TEER measures the electrical resistance across a cell monolayer, providing a quantitative assessment of the tightness or integrity of cell junctions within an epithelial barrier. High TEER values indicate a strong, intact barrier, while low values suggest a compromised, leaky barrier – a hallmark of diarrhea. 2️⃣ Modeling Diarrhea Diarrhea can be simulated in vitro by exposing intestinal epithelial cells to stimuli that disrupt barrier function, such as inflammatory cytokines or toxins. By measuring TEER, we can assess how these agents alter barrier integrity over time, allowing us to pinpoint mechanisms and potential interventions. 3️⃣ TEER in Drug Development Understanding how new drugs affect the intestinal barrier before clinical trials helps identify and mitigate side effects early. TEER models are also ethically favorable, reducing reliance on animal testing. At Altis Biosystems, we use an automated system that measures TEER in a 96-well plate within minutes. This state-of-the-art equipment enables high-throughput, real time assessment of drug-induced barrier disruptions. Explore our website to learn how we can help with disease modeling and more ➡️https://hubs.ly/Q02WkhZM0

RepliGut® Models mimic in vivo responses to support a variety of research and pharmacological applications. Explore RepliGut® applications: https://hubs.ly/Q02V-_NJ0

💡More than one-third of patients receiving chemotherapy treatment will experience severe diarrhea. Chemotherapeutic agents often target actively proliferating cells. During preclinical studies, drug- induced toxicity may go undetected in differentiated cell models that lack this cell population. In our latest preprint, we show that anti-mitotic drugs afatinib and colchicine are cytotoxic to proliferative cells while sparing differentiated cells. Read more about how our primary stem-cell based assay can predict drug-induced toxicity with up to 90% accuracy. https://hubs.ly/Q02VDNvY0

RepliGut® StemTox is a rapid and robust assay to predict drug-induced gastrointestinal toxicity in a 96-well plate. Read our latest preprint to find out how this assay detects potential adverse effects before human trials https://hubs.ly/Q02VsBL30

A stem cell begins its journey at the base of the intestinal crypt, continuously dividing to produce new cells. As the stem cell differentiates, it gives rise to transit amplifying cells that proliferate and gradually differentiate into specialized cell types, such as enterocytes, goblet cells, and enteroendocrine cells. This constant turnover drives cell migration along the epithelial layer. During this ascent, the cells mature and take on their specific functions, such as nutrient absorption or mucus secretion. At the top of the crypt, the fully differentiated cells are shed into the intestinal lumen, contributing to the gut's overall functionality and integrity. This process is crucial for maintaining a healthy intestinal barrier and ensuring efficient nutrient absorption. 💡It's essential to utilize models that accurately replicate the intestinal crypt environment, as they better simulate the complex interactions between cell types. Discover the versatility of our RepliGut® Technology and find out how it can accelerate your drug discovery programs: https://hubs.ly/Q02V8N4M0

One of the standout features of our RepliGut® technology is its innovative approach to drug testing. The sequential proliferation and differentiation phases enable researchers to independently explore drug effects on both proliferative and fully differentiated intestinal epithelial cells. Visit our website for more details: https://hubs.ly/Q02TP3GJ0

Intestinal mucus is an important mediator of bacterial interactions, enabling both beneficial and harmful microbes to thrive and compete within the host. 🦠 Altis now offers RepliGut® Mucus produced by primary human intestinal epithelial cells. 📖Read about how RepliGut® Mucus can be used to study bacterial interactions: https://hubs.ly/Q02SLbrD0 Contact us today to learn more or obtain a quote: https://hubs.ly/Q02SLbHx0